<DOC>
	<DOCNO>NCT02815566</DOCNO>
	<brief_summary>Design : Double-blind placebo control randomised multicenter international strategic trial old woman combination antiretroviral therapy ( cART ) contain tenofovir-emtricitabine ( TDF/FTC ) HIV RNA suppression &gt; 6 month : 1 . Immediate switch TDF/FTC tenofovir alafenamide-emtricitabine ( TAF/FTC ) continue third antiretroviral agent . ; 2 . Delayed switch ; switch TDF/FTC TAF/FTC 48 week continue third agent . Follow subject 96 week . Subject Population : The anticipated sample size 128 HIV infected woman age 45-55 year ( peri early post menopause ) . . Primary endpoint : Percentage change baseline bone mineral density ( BMD ) lumbar spine week 48 96 . Secondary Endpoints : BMD change hip , trabecular bone score , estimate bone strength high resolution peripheral quantitative computerize tomography ( HR-pQCT ) , muscle quality , geriatric assessment ; biomarkers bone , immune activation inflammation ; HIV viral suppression ; safety , lipid renal function , cardiovascular risk score week 48 96 . Expected Outcomes : To determine switch TDF/FTC TAF ? FTC improve BMD degree correlate decrease risk fragility fracture age HIV infected woman . Secondary outcome assess bone strength use new image modality , time switch , renal health . This data use health policy maker provider determine proper use TAF ? FTC age HIV population .</brief_summary>
	<brief_title>Bone Health Aging HIV Infected Women</brief_title>
	<detailed_description>A Randomized control clinical trial ( RCT ) immediate vs delay switch TDF/FTC TAF/FTC define impact switch ARV BMD different stage age trajectory HIV infect woman . Included geriatric assessment base conceptualization health transition across menopause . Study Hypothesis : The primary hypothesis switch TDF/FTC improve BMD degree correlate low fracture risk age HIV+ woman . We explore theory impact great early stage menopause also receive protease inhibitor ( PI ) third antiretroviral agent ( ARV ) . Primary objective : To determine : 1 . Switching HIV+ woman TDF/FTC TAF/FTC increase BMD spine 48 week relative continue TDF/FTC 2 . To determine observed improvement continue stabilize year switch . Hypothesis generate objective : To determine effect switch TDF/FTC TAF/FTC BMD vary stage menopause third ARV . Study design : This study double blind placebo control randomise , 1:1 , multicentre strategic trial . Patients randomise immediate v delay switch , randomization allocation arrange minimize difference treatment group respect stage menopause ( peri- menopause vs early post menopause ) site . Study population : HIV positive woman peri-menopausal period within 10 year post menopause capture great risk BMD loss . As menopause typically occur early HIV + woman include age 45-55 year . They must cART regimen contain TDF/FTC HIV RNA &lt; 50 c/ml least 6 month . Intervention : 1 . Immediate switch TDF/FTC TAF/FTC maintain third ARV agent . 2 . Delayed switch TDF/FTC TAF/FTC 48 week maintain third ARV agent . Randomization : A computer-generated randomization list prepare prior study onset statistician unassociated study University Health Network . Randomization stratify study centre . Primary endpoint : Comparison immediate vs delay group % change baseline BMD lumbar spine week 48 96 . Secondary endpoint : Will compare change immediate delay group data collect screen baseline week 48 96 . - change baseline BMD hip Changes Bone architecture determine Trabecular bone scan ( TBS ) HRpQCT ( high resolution peripheral quantitative computerize tomography ) ( Toronto site ) Changes 10 year fracture risk determine country specific FRAX® ( fracture risk assessment ) calculator - HIV-1 RNA &lt; 50 c/ml Change baseline geriatric functional measure : frailty , performance balance Change baseline muscle quality : Sarcopenia - grip strength measure Dynamometer Change baseline lipid value Framingham cardiovascular risk score Changes renal tubular glomerular function : GFR ( glomerular filtration rate ) , Creatinine , urine albumin /creatinine protein/creatinine , glucosuria Safety ( clinical laboratory adverse event ) Changes biomarkers inflammation , coagulation bone metabolism Tolerability ( EuroQoL questionnaire )</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<criteria>1 . Biological female age 4555 2 . Documented HIV1 infection 3 . Perimenopausal within 10 year menopause ( documented history ) . 4 . Signed Informed Consent Form willing comply protocol . 5 . Receiving cART regimen contain ritonavir boost PI ( darunavir , atazanavir , lopinavir , ) NNRTI ( efavirenz , nevirapine rilpivirine ) integrase inhibitor ( dolutegravir raltegravir elvitegravir ) combination TDFFTC &gt; 24 week . 6 . Stable viral suppression ( plasma HIVRNA &lt; 50 copies/mL &gt; 24 week ) . Single viral blip &lt; 500/ml allow resuppresses . 7 . If childbearing potential , use effective birth control method willing continue trial . 8 . Women assess vitamin D calcium dietary intake ; inadequate age , supplement recommend . 1 . HIV2 2 . High 10year fracture risk baseline ( &gt; 20 % ) base country specific FRAX 3 . Current treatment active bone medication bisphosphonates , denosumab , calcitonin , raloxifene , teriparatide , strontium 4 . Current use systemic steroid ( inhaled steroid permit ) chemotherapeutic agent 5 . Acute viral hepatitis 6 . Chronic hepatitis C liver transaminases &gt; 5 x ULN expect require treatment hepatitis C trial period . 7 . Any investigational ARV within 30 day . 8 . Dialysis renal insufficiency ( creatinine clearance &lt; 50ml/min ) 9 . History decompensated liver disease ( AST ALT≥5x upper limit normal ( ULN ) ALT ≥ 3 x ULN bilirubin ≥ 1.5 x ULN &gt; 35 % direct bilirubin ) , presence ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal gastric varix . 10 . Pregnant breastfeed 11 . Screening blood result grade 3/4 toxicity accord Division AIDS ( DAIDS ) grade scale , except : asymptomatic grade 3 amylase , creatinine phosphokinase , lipid elevation . 12 . Any condition ( include illicit drug use alcohol abuse ) lab result , investigator 's opinion , interfere assessment completion trial .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>kidney , antiretroviral agent , tenofovir , osteoporosis , woman</keyword>
</DOC>